Lixisenatide Acetate
Metabolic
It has phase III human research in type 2 diabetes, including add on studies with basal insulin and metformin.
An authorisation applies to at least one defined finished product in a stated jurisdiction; it does not apply automatically to this catalogue material.
What is Lixisenatide Acetate?
Lixisenatide acetate is a synthetic glucagon like peptide 1 receptor agonist peptide studied in metabolic and phase III diabetes research; the catalogue label denotes the acetate salt research material supplied for laboratory investigation.
Which research context has Lixisenatide Acetate been associated with?
Lixisenatide Acetate is associated with metabolic research as a synthetic glucagon like peptide 1 receptor agonist peptide, with phase III clinical studies in type 2 diabetes, including add on regimens with basal insulin and metformin.
What documentation is available for Lixisenatide Acetate?
Lixisenatide Acetate: Batch documents are not yet linked on this site. For this synthetic glucagon like peptide 1 receptor agonist peptide the expected evidence includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and purity specification; peptide content, counterion and residual solvent/water details; and potency/assay documentation for release. No batch documentation is shown as available until the record for that specific item is linked and reviewed.
What determines the storage conditions for Lixisenatide Acetate?
Lixisenatide Acetate: Storage depends on the documented supplied presentation; as a synthetic glucagon like peptide 1 receptor agonist peptide verify dry/lyophilised versus solution form, counterion and concentration, solvent or buffer composition, pH sensitivity, container closure compatibility and aggregation or proteolysis risks that determine stability. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.